Note of Intent to Award Sole Source

The United States Army Medical Research Acquisitions Activity (USAMRAA), acting on behalf of the United States Army Medical Materiel Development Activity (USAMMDA), has issued a Special Notice of Intent to Modify an Existing Contract within Scope for a project involving Cryopreserved Platelets (CPP). The notice is published by the Defense Health Agency and specifically relates to contract W81XWH-20-C-0030-P00017. Market research conducted in October 2024 revealed no other FDA-licensed companies or intellectual property for CPP in the United States, with limited research existing only in the Netherlands and Australia. The notice is categorized under NAICS code 541715 for Research and Development in Physical, Engineering, and Life Sciences, with a size standard of 1,250 employees. This is not a request for proposals, and the government does not commit to covering costs associated with preparing or submitting data in response to the notice.

The primary purpose of this Special Notice is to increase the cost ceiling of the existing contract to accommodate additional research activities, including enrollment of up to 400 subjects, consultant costs, professional travel, materials, regulatory expenses, and site activations. Contractors interested in responding must submit written responses with supporting evidence within 15 days of publication. All questions regarding the notice are due by 3:00 PM Eastern Time on January 20, 2025, and must be submitted to Peter Mitchell at peter.d.mitchell8.civ@health.mil. The modification is driven by the need to demonstrate non-inferiority between CryoPreserved and Liquid Stored Platelets, which requires an expanded subject pool. While no specific eligibility criteria are explicitly stated, the NAICS classification and employee size standard suggest that potential contractors should be research and development organizations specializing in life sciences with fewer than 1,250 employees. The opportunity represents a targeted research initiative within the defense health sector aimed at advancing platelet preservation techniques.